The Irish Times Business Person of the Month: Matt Cooper Inflazome sells to Swiss pharma giant Roche for an initial €380 million
Tue, Apr 13, 2021, 02:06
The spark behind Inflazome came when Australian chemist Matt Cooper met Irish immunologist Luke O’Neill at a medical conference. The two men brainstormed the role of inflammasomes - part of the body’s immune system - in a host of serious chronic diseases when they spiral out of control.
Eight years later - and four years after the two men set up the company in Dublin - Inflazome was sold to Swiss pharma giant Roche for an initial €380 million.
"We have scaled up the production of remdesivir by 2x from the last wave of the pandemic," Cipla said in a statement. "Given the unprecedented demand for the drug, we have now further ramped up our capacities through our network."
Apr 13, 2021 11:58am The Mallya device, compatible with most disposable insulin pens, automatically transmits daily insulin data to diabetes patients’ healthcare providers via Roche’s Gluci-Chek app. (Roche)
Need to automatically compile data gathered by an insulin pen and send it to a healthcare provider? There’s a device-connected app for that.
Less than a year after signing their initial distribution agreement, Roche Diabetes Care France has begun making Biocorp’s Mallya device available in pharmacies across France.
The French device maker’s smart sensor connects to most disposable insulin injection pens to collect data about each injection. Mallya automatically transmits that data to Roche’s Gluci-Chek smartphone app over Bluetooth. The dosage, insulin type, date and time information can then be logged and shared with healthcare providers via the Roche Diabetes Care Platform.
F. Hoffmann-La Roche Ltd: Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%
Placebo
Risk reduction
13
1.2
4 copies/mL)
14
0.4
Individuals without any COVID-19 symptoms who lived in the same household as an individual who tested positive to SARS-CoV-2 within the prior four days
. Based on the seronegative modified Full Analysis Set population, which includes all randomized subjects without evidence of current or prior SARS-CoV-2 infection (i.e., a negative RT-qPCR test and a negative antibody test) at randomization.
Adverse events (AEs) occurred in 20% (n=265 out of 1,311) of REGEN-COV participants and 29% (n=379 out of 1,306) of placebo participants, and serious AEs occurred in 1% (n=10) of REGEN-COV participants and 1% (n=15) of placebo participants. There were 0 REGEN-COV participants and 4 placebo participants who were either hospitali
Regeneron, Roche injectable antibody drug shows efficacy in preventing Covid-19
A Regeneron Pharmaceuticals antibody cocktail currently authorized for treating Covid-19 now has additional clinical data showing it reduces the risk of infection spread. The drug developer, along with partner Roche, plan to ask regulators to expand the drug’s authorization to include disease prevention.
Shares0
A Covid-19 antibody cocktail developed by Regeneron Pharmaceuticals and Roche has pivotal clinical trial data showing it protected against the spread of infection among people in the same household. The results support use of the drug as a preventative measure in a formulation that’s easier for both physicians and patients.